Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer

医学 列线图 前列腺切除术 前列腺癌 生化复发 阶段(地层学) 手术切缘 前列腺特异性抗原 根治性耻骨后前列腺切除术 活检 泌尿科 癌症 淋巴结 比例危险模型 前列腺 局限性疾病 外科 肿瘤科 内科学 古生物学 生物
作者
Michael W. Kattan,Thomas M. Wheeler,Peter T. Scardino
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:17 (5): 1499-1499 被引量:683
标识
DOI:10.1200/jco.1999.17.5.1499
摘要

PURPOSE: Although models exist that place patients into discrete groups at various risks for disease recurrence after surgery for prostate cancer, we know of no published work that combines pathologic factors to predict an individual's probability of disease recurrence. Because clinical stage and biopsy Gleason grade only approximate pathologic stage and Gleason grade in the prostatectomy specimen, prediction of prognosis should be more accurate when postoperative information is added to preoperative variables. Therefore, we developed a postoperative nomogram that allows more accurate prediction of probability for disease recurrence for patients who have received radical prostatectomy as treatment for prostate cancer, compared with the preoperative nomogram we previously published. PATIENTS AND METHODS: By Cox proportional hazards regression analysis, we modeled the clinical and pathologic data and disease follow-up for 996 men with clinical stage T1a-T3c NXM0 prostate cancer who were treated with radical prostatectomy by a single surgeon at our institution. Prognostic variables included pretreatment serum prostate-specific antigen level, specimen Gleason sum, prostatic capsular invasion, surgical margin status, seminal vesicle invasion, and lymph node status. Treatment failure was recorded when there was either clinical evidence of disease recurrence, a rising serum prostate-specific antigen level (two measurements of 0.4 ng/mL or greater and rising), or initiation of adjuvant therapy. Validation was performed on this set of men and a separate sample of 322 men from five other surgeons' practices from our institution. RESULTS: Cancer recurrence was noted in 189 of the 996 men, and the recurrence-free group had a median follow-up period of 37 months (range, 1 to 168 months). The 7-year recurrence-free probability for the cohort was 73% (95% confidence interval, 68% to 76%). The predictions from the nomogram appeared to be accurate and discriminating, with a validation sample area under the receiver operating characteristic curve (ie, a comparison of the predicted probability with the actual outcome) of 0.89. CONCLUSION: A postoperative nomogram has been developed that can be used to predict the 7-year probability of disease recurrence among men treated with radical prostatectomy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Cookiee完成签到,获得积分10
刚刚
科研通AI6.2应助张张采纳,获得10
1秒前
与人完成签到,获得积分10
2秒前
3秒前
罗钟山发布了新的文献求助10
5秒前
长空栈道完成签到,获得积分10
7秒前
xyzzzz完成签到,获得积分20
8秒前
笨笨静槐发布了新的文献求助10
10秒前
10秒前
11秒前
情怀应助熙熙采纳,获得20
12秒前
13秒前
叶可颖完成签到,获得积分10
14秒前
14秒前
有机小鸟完成签到,获得积分10
15秒前
Tiger发布了新的文献求助10
16秒前
Luke完成签到,获得积分10
16秒前
16秒前
17秒前
18秒前
DYH发布了新的文献求助10
19秒前
123123发布了新的文献求助10
19秒前
深情安青应助哈哈哈哈采纳,获得10
19秒前
我鬼混回来了完成签到 ,获得积分10
21秒前
21秒前
袁晨阳发布了新的文献求助10
22秒前
王怡然完成签到 ,获得积分10
23秒前
24秒前
郜不正发布了新的文献求助10
24秒前
虎咪咪完成签到,获得积分10
25秒前
小凯发布了新的文献求助50
25秒前
25秒前
zsk1122发布了新的文献求助30
27秒前
chuyyyy发布了新的文献求助10
27秒前
27秒前
28秒前
xyzzzz发布了新的文献求助20
29秒前
30秒前
涂涂发布了新的文献求助10
30秒前
香蕉觅云应助砍柴少年采纳,获得10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6518372
求助须知:如何正确求助?哪些是违规求助? 8311109
关于积分的说明 17768328
捐赠科研通 5620302
什么是DOI,文献DOI怎么找? 2926261
邀请新用户注册赠送积分活动 1903127
关于科研通互助平台的介绍 1763988